Lilly Pays Nektar US$150 M Upfront to Co-Develop Broad Immunological Therapy
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 9 (Table of Contents)
Published: 2 Sep-2017
DOI: 10.3833/pdr.v2017.i9.2271 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Eli Lilly has paid US$150 M upfront as part of a collaboration with Nektar Therapeutics to co-develop NKTR-358, a Phase I T-cell regulator that could potentially act on a wide range of inflammatory and autoimmune disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS